Login
$ARTV
$3.94 -$0.02 (0.51%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Fred Aslan Also a director
Chief Executive Officer and Director
52 Not stated Not stated $6,671,215
Jennifer Bush
Chief Operating Officer, Chief Legal Officer and Compliance Officer
51 Not stated Not stated $1,536,715
Subhashis Banerjee
Chief Medical Officer
70 Since 2025
1 year
2025 Not reported
Christopher P. Horan
Chief Tech Operations Officer
Title from the Form 4 dated Nov 2, 2026
59 Not stated 2021 $1,415,855
Diego Miralles
President & Head of R&D
Title from the Form 4 dated Sep 9, 2026
63 Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
3.6 years
from year joined
CEO also chairs the board
No
Brian Daniels, M.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Brian Daniels, M.D.
67 2020
6 years
Independent
Clinical Development Committee · Chair Compensation Committee · Chair
CSL Ltd. $117,357
Fred Aslan, M.D.
52 2021
5 years
Not stated None stated None stated Paid as CEO
Laura Stoppel, Ph.D.
40 2020
6 years
Independent None stated Acumen Pharmaceuticals, Inc. $71,249
Elaine Sorg
59 2026
this year
Independent
Audit Committee Commercial Planning Committee · Chair
CSL Limited Not stated
Daniel Baker, M.D.
75 2025
1 year
Independent
Compensation Committee Clinical Development Committee Commercial Planning Committee Nominating and Corporate Governance Committee · Chair
Shattuck Labs, Inc. $180,527
Elizabeth Hougen
65 2021
5 years
Independent
Audit Committee · Chair
None stated $71,390
Alison Moore, Ph.D.
59 2024
2 years
Independent None stated None stated $71,390

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

9 disclosed in the proxy filed Aug 3, 2026
GC Corp. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 5,614,424

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
5AM Ventures VI, L.P. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 4,709,212

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
venBio Global Strategic Fund III, L.P.
holder of more than 5% of our capital stock, or entities affiliated with them
$ 4,709,212

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
RA Capital Healthcare Fund, L.P. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 4,709,212

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
Venrock Healthcare Capital Partners EG, L.P. and its affiliate
holder of more than 5% of our capital stock, or entities affiliated with them
$ 3,689,300

Participation in the SAFE financing (Simple Agreements for Future Equity) in September and November 2023.

With Company Open in proxy
GC Cell
owner of more than 5% of our outstanding capital stock at the time of execution of the Manufacturing Agreement; affiliated with directors Yu-Kyeong Hwang, Ph.D. and Yong-Jun Huh
$2.9 million and $3.7 million
2024 and 2023

Master Manufacturing Agreement under which we incurred manufacturing-related costs.

With Company Open in proxy
GC Cell
owner of more than 5% of our outstanding capital stock at the time of execution of the AB-201 Agreement; affiliated with directors Yu-Kyeong Hwang, Ph.D., Yong-Jun Huh and James Park
$0.3 million

AB-201 Selected Product License Agreement under which we paid a one-time upfront fee to GC Cell.

With Company Open in proxy
Blackbird Clinical, Inc.
entity controlled by RA Capital, which owned more than 5% of our outstanding capital stock; Laura Stoppel, Ph.D., a member of our Board, is affiliated with RA Capital
Zero and $0.3 million
2025 and 2024

Services agreement under which Blackbird provides consulting services for our clinical trials.

With Blackbird Clinical, Inc. Open in proxy
Carnot Pharma, LLC
entity controlled by RA Capital, which owned more than 5% of our outstanding capital stock; Laura Stoppel, Ph.D., a member of our Board, is affiliated with RA Capital
$31 thousand and $15 thousand
2025 and 2024

Services agreement under which Carnot provides consulting services for our clinical trials.

With Carnot Pharma, LLC Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support